Topics

Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

11:12 EST 7 Nov 2019 | SCRIP

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price...

      

Related Stories

 

Original Article: Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

NEXT ARTICLE

More From BioPortfolio on "Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...